Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Nose zap might stop migraines before they start

NCT ID NCT07279623

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a small device placed inside the nose that delivers gentle stimulation to prevent migraines. 110 adults with migraines will use the device at home every other day for six weeks. Researchers will track how many migraine days they have compared to a group that starts treatment later. The goal is to see if this drug-free approach is safe and effective for migraine prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-65 years at the time of screening. 2. The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject. 3. Onset of migraine headache occurred before age 50. 4. History of migraines for at least 1 year before screening. 5. The study subject reports at least 8 monthly migraine days during the screening period. 6. If subject is on a prophylactic migraine medication regimen: 1. Reports stable medication regimen during the three months prior to screening. 2. Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up. 7. The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments. 8. Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study. 9. Anticipated compliance with prescribed treatment and follow-up. Exclusion Criteria: 1. Subject unable to distinguish between migraine headaches and other headache types. 2. Recently (12 months prior screening) undergone nasal or sinus surgery. 3. Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation. 4. Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s. 5. Subject is pregnant or lactating or planning to get pregnant during the duration of the study. 6. The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation. 7. The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • INMEST-mottagningen Odenplan

    RECRUITING

    Stockholm, 11327, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.